Results 21 to 30 of about 17,264 (156)

Factor Xa inhibitor for venous thromboembolism management in patient with cancer: a systematic review and meta-analysis [version 1; peer review: 2 approved]

F1000Research, 2021
Background: An earlier systematic review reported no differences in the incidence of recurrent venous thromboembolism and major bleeding between factor Xa inhibitors and standard anticoagulation.
Ardyan Wardhana, Johanes Nugroho Eko Putranto, Pirhot Lambok Marnala Yosua Siahaan, Yoga Alfian Noor, Makhyan Jibril Al Farabi   +4 more
doaj   +1 more source

Recommendations for the use of andexanet alfa in the management of bleeding in patients on oral factor Xa inhibitors in Switzerland

Swiss Medical Weekly, 2023
Anticoagulants are essential in preventing and treating thrombosis. Unfortunately, their use is accompanied by an enhanced risk of bleeding. Since the introduction of direct oral anticoagulants (DOACs), the risk of major bleeding has been reduced but ...
Anne Angelillo-Scherrer, Alessandro Casini, Jan-Dirk Studt, Bernhard Gerber, Lorenzo A. Alberio, Pierre Fontana   +5 more
doaj   +1 more source

Prediction of inhibition constants of (R)-3-amidinophenylalanine inhibitors toward factor Xa by 2D-QSAR model

Vietnam Journal of Science, Technology and Engineering, 2022
A coagulation cascade forms through proteolytic reactions and involves different factors. There are two coagulation pathways, including intrinsic and extrinsic mechanisms, which converge by the formation of factor Xa.
Thi Bich Van Pham, Minh Hao Hoang
doaj   +1 more source

Warfarin versus factor Xa inhibitors in the long-term treatment of cerebral venous sinus thrombosis a single-center retrospective analysis

eNeurologicalSci, 2022
Long-term anticoagulation in the treatment of Cerebral Venous Sinus Thrombosis (CVST) has revolved around the use of warfarin. The relatively recent introduction of Direct Oral Anticoagulants (DOACs), such as Factor Xa inhibitors, in treating CVSTs ...
Alexei Christodoulides, Bradley N. Bohnstedt   +1 more
doaj   +1 more source

Heavy menstrual bleeding on direct factor Xa inhibitors: Rationale and design of the MEDEA study

Research and Practice in Thrombosis and Haemostasis, 2021
Background In premenopausal women, treatment with direct oral factor Xa inhibitors is associated with an increased risk of heavy menstrual bleeding (HMB) compared with vitamin K antagonists (VKA).
Eva N. Hamulyák, Hanke M. G. Wiegers, Luuk J. J. Scheres, Barbara A. Hutten, Maria E. deLange, Anne Timmermans, Peter E. Westerweel, Marten R. Nijziel, Marieke J. H. A. Kruip, Marije ten Wolde, Paula F. Ypma, Frederikus A. Klok, Laurens Nieuwenhuizen, Sanne vanWissen, Marcel M. C. Hovens, Laura M. Faber, Pieter W. Kamphuisen, Harry R. Büller, Saskia Middeldorp   +18 more
doaj   +1 more source

Evolutionary dynamics on a regular networked structured and unstructured multi‐population

International Journal of Robust and Nonlinear Control, EarlyView., 2023
Abstract In this paper, we study collective decision‐making in a multi‐population framework, where groups of individuals represent whole populations that interact by means of a regular network. Each group consists of a number of players and every player can choose between two options.
Wouter Baar, Leonardo Stella, Dario Bauso   +2 more
wiley   +1 more source

PREDICTORS OF THE RISK OF HEMORRHAGIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION RECEIVING LONGTERM THERAPY WITH DIRECT ORAL ANTICOAGULANTS

Рациональная фармакотерапия в кардиологии, 2017
Aim. To study the initial disorders in the coagulation system, as factors influencing the development of bleeding during anticoagulant therapy with direct oral anticoagulants (DOAC).Material and methods.
A. А. Sokolova, A. V. Zhilenko, I. L. Tsarev,, D. A. Napalkov, V. V. Fomin   +4 more
doaj   +1 more source

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors

Nature Communications, 2017
A major drawback in the clinical use of the oral anticoagulants that directly inhibit factor Xa in order to prevent blood clot formation is the potential for life threatening bleeding events.
Daniël Verhoef, Koen M. Visscher, C. Ruben Vosmeer, Ka Lei Cheung, Pieter H. Reitsma, Daan P. Geerke, Mettine H. A. Bos   +6 more
doaj   +1 more source

Efficacy and Toxicity of Factor Xa Inhibitors

Journal of Pharmacy & Pharmaceutical Sciences, 2013
Venous thromboembolism (VTE) is a serious disease that is often neglected, and effective and safe antithrombotic treatments are a public health priority.
Maryna Bondarenko, Christophe Curti, Marc Montana, Pascal Rathelot, Patrice Vanelle   +4 more
doaj   +1 more source

Gla-domainless factor Xa: molecular bait to bypass a blocked tenase complex

Haematologica, 2012
Background Hemophilia is caused by deficiencies in coagulation factor VIII or IX, resulting in direct blockade of the intrinsic tenase complex and indirect blockade of the extrinsic tenase complex which is rapidly inhibited upon binding of factor Xa to ...
Raphaël Marlu, Benoît Polack
doaj   +1 more source